Clozapine

Neuroleptic malignant syndrome associated with clozapine use.

Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry. 1991;52(3):102-4. PubMed PMID: 2005071.

Neuroleptic malignant syndrome and clozapine monotherapy.

Chatterton R, Cardy S, Schramm TM. Neuroleptic malignant syndrome and clozapine monotherapy. Aust N Z J Psychiatry. 1996;30(5):692-3. DOI: 10.3109/00048679609062668. PubMed PMID: 8902179.

An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge.

Goates MG, Escobar JI. An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge. J Clin Psychopharmacol. 1992;12(2):139-40. PubMed PMID: 1573039.

Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.

Huang TL. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. Chang Gung Med J. 2001;24(8):522-5. PubMed PMID: 11601195.

Neuroleptic malignant syndrome associated with clozapine treatment.

Tsai G, Crisostomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry. 1995;7(2):91-5. PubMed PMID: 8556099.

Clinical correlates of clozapine prescription for schizophrenia in China.

Xiang Y-T, Weng Y-Z, Leung C-M, Tang W-K, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum. Psychopharmacol. Clin. Exp. 2007;22(1):17-25. DOI: 10.1002/hup.821. PubMed PMID: 17191268.

Clozapine resistance: augmentation strategies.

Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. European Neuropsychopharmacol. 2012;22(3):165-82. DOI: 10.1016/j.euroneuro.2011.08.005. PubMed PMID: 21906915.

Psychopharmacology: underuse of evidence-based treatments in psychiatry.

Fayek M, Flowers C, Signorelli D, Simpson G. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatr Serv. 2003;54(11):1453-4, 1456. PubMed PMID: 14600298.

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia.

Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry. 1999;60 Suppl 12:9-12. PubMed PMID: 10372603.

The evolution of treatment resistance: biologic implications.

Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biologic implications. J Clin Psychopharmacol. 1998;18(2 Suppl 1):5S-11S. PubMed PMID: 9555610.